Food and Drug Administration regulation and evaluation of vaccines

Pediatrics

Volumn 127, Issue SUPPL. 1, 2011, Pages

  Marshall, Valerie ^a   Baylor, Norman W ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Biologics licensing; Regulation; Vaccine

Indexed keywords

VACCINE;

DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; INTERNATIONAL COOPERATION; LAW; LICENSING; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; REVIEW; UNITED STATES; VACCINE PRODUCTION;

ANIMALS; DRUG APPROVAL; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; GUIDELINES AS TOPIC; HUMANS; LICENSURE; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY CONTROL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES;

EID: 79955488319     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1722E     Document Type: Review

References (39)

1. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children: United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999;48(12):243-248
2. Food Drug and Cosmetic Act, 21 USC §321 (1938)
3. Public Health Service Act, ch 373, title III, §351, 58, Stat. 702, 42 USC §262 (1944)
4. Biologics Control Act of 1902, Pub L No. 57-244, ch 1378, 32 Stat 728
5. Offit P. The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. New Haven, CT: Yale University Press; 2005
6. Code of Federal Regulations, 21 CFR parts 600-680 (2010)
7. Code of Federal Regulations, 21 CFR parts 210 and 211 (2010)
8. Prescription Drug User Fee Act, Pub L No. 102-571 (1992)
9. Food and Drug Administration Modernization Act of 1997, Pub L No. 105-115 (1997)
10. Best Pharmaceuticals for Children Act, Pub L No. 107-109 (2002)
11. Food and Drug Administration Amendments Act of 2007, Pub L No. 110-85 (2007)
12. Pediatric Research Equity Act, Pub L No. 108-155 (2003)
13. Code of Federal Regulations, 21 CFR part 58 (2010)
14. US Food and Drug Administration. Draft guidance for industry: considerations for reproductive toxicity studies for preventive vaccines for infectious disease indications. Available at: www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm092267.pdf. Accessed January, 2010
15. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for industry: formal meetings between the FDA and sponsors or applicants. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/drugs/ GuidanceComplianceRegulatoryInformation/guidances/ucm153222.pdf. Accessed January, 2010
16. Code of Federal Regulations, 21 CFR 312 (2010)
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: guideline for good clinical practice E6(R1). Available at: www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ Eb-R1-Guideline.pdf. Accessed January, 2010
18. Code of Federal Regulations, 21 CFR part 312.42 (2010)
19. Code of Federal Regulations, 21 CFR part 312.21 (2010)
20. Code of Federal Regulations, 21 CFR parts 600-680 (2010)
21. Code of Federal Regulations, 21 CFR part 600 (2010)
22. Center for Biologics Evaluation and Research. Guidance for industry: characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm092122.pdf. Accessed January, 2010
23. Code of Federal Regulations, 21 CFR 201 and 610.10-610.62 (2009)
24. Code of Federal Regulations, 21 CFR Part 601.41 (2010)
25. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for Industry: Fast Track drug development programs-designation, development, and application review. US Department of Health and Human Services, Food and Drug Administration. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM079736.pdf. Accessed January, 2010
26. Code of Federal Regulations, 21 CFR part 601.90 (2009)
27. Code of Federal Regulations, 21 CFR 610 (2009)
28. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. 11th ed. Washington, DC: Public Health Foundation; 2009
29. National Childhood Vaccine Injury Act, Pub L No. 99-660 (1986)
30. Center for Biologics Evaluation and Research. Guidance for industry: development of preventive HIV vaccines for use in pediatric populations. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092165.pdf. Accessed January, 2010
31. Center for Biologics Evaluation and Research. Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091968.pdf. Accessed January, 2010
32. Center for Biologics Evaluation and Research. Guidance for industry: content and format of chemistry, manufacturing and controls information and establishment description information for a vaccine or related product. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092272.pdf. Accessed January, 2010
33. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH tripartite guideline. Pharmaceutical Quality System Q10. Available at: www.ich.org/fileadmin/Public- Web-Site/ICH-Products/Guidelines/Quality/Q10/Step4/Q10-Guideline.pdf. Accessed January, 2010
34. Center for Biologics Evaluation and Research. Draft Guidance for industry: process validation: general principles and practices. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070336.pdf. Accessed January, 2010
35. Center for Biologics Evaluation and Research. Guidance for industry: Clinical data needed to support the licensure of pandemic influenza vaccines. US Department of Health and Human Services, Food and Drug Administration. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf. Accessed January, 2010
36. Center for Biologics Evaluation and Research. Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf. Accessed January, 2010
37. Center for Biologics Evaluation and Research. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. US Department of Health and Human Services, Food and Drug Administration. Available at: www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm091977.pdf. Accessed January, 2010
38. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Tripartite Guideline. Detection of toxicity to reproduction for medicinal products and toxicity to male fertility S5(R2). Available at: www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Safety/S5-R2/Step4/S5-R2-Guideline.pdf. Accessed January, 2010
39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Tripartite Guideline. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Available at: www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Safety/S6-R1/Step4/S6-Guideline.pdf. Accessed January, 2010